AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04468451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A 24-hour ROC training program with a standing posture
Description: The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
Study NCT04468451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A regular therapy program without receiving any ROC training
Description: The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
Study NCT05712798 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02225743 — intervention group
Intervention type: OTHER
Intervention: Observation Of Temperature
Description: Participants temperature will be recorded perioperatively.
Study NCT03249311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Study NCT03249311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Study NCT03249311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Study NCT01879774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological and motoric tests
Description: 1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)
Study NCT02574130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: 400 mg, nebulizer, every 12 hours, 10 days
Study NCT02574130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 4 ml, nebulizer, every 12 hours, 10 days
Study NCT03893604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2) 2mA or sham
Study NCT03893604 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2) 2mA or sham
Study NCT00322842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study NCT01264978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation of the quadriceps muscle
Description: During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions.
Study NCT02068222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/ritonavir (r)
Description: Tablet
Study NCT01208025 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
Description: 3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
Study NCT03027180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive airway pressure with different levels
Study NCT03027180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive airway pressure with different levels
Study NCT01190280 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy operation
Description: Cholecystectomy after randomization
Study NCT02857049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) degustation
Study NCT01087151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral repeating dose
Study NCT04713332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
Study NCT01932775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoTab System
Study NCT01087151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT00832052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
Study NCT00832052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
Study NCT00832052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
Study NCT00832052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
Study NCT04476394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Anaprazole Sodium enteric-coated capsule
Description: \[14C\]-Anaprazole Sodium enteric-coated capsule
Study NCT03335254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-011
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
Study NCT01087151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT03942107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single-visit RCT
Description: both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
Study NCT02580513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Misalignment
Study NCT00587847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Campath
Description: Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
Study NCT00784680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily
Study NCT00343382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilocarpine hydrochloride
Description: Given orally
Study NCT00343382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02601547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-FDG brain imaging and NPT
Description: PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
Study NCT04032080 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug 1: LY3023414; Drug 2: Prexasertib
Description: Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses.
Study NCT00000572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: positive-pressure ventilation
Description: Detailed computer protocol controlled positive pressure ventilation
Study NCT00784680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily
Study NCT02068222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet
Study NCT02068222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study NCT02380664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (Powerplate®)
Description: Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
Study NCT02380664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping intervention
Description: Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
Study NCT03942107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: two-visit RCT
Description: after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
Study NCT03995394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Reinforcement Text Message
Description: A text message comprising the words, Great job! We're so proud of you! Keep up the good work!
Study NCT02168855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active nicotine gum
Description: 2 mg, standard over-the-counter nicotine replacement therapy gum
Study NCT02168855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral therapy
Description: Standard behavioral therapy for smoking cessation
Study NCT02168855 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard behavioral therapy
Description: Standard behavioral therapy for smoking cessation
Study NCT04490694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT04490694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
Study NCT02991573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prime & Bond Universal
Description: Prime \& Bond Universal
Study NCT01237665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXO regimen
Description: IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22.
Study NCT00705627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy plus concurrent chemoradiotherapy
Description: Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
Study NCT03500315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV D+/R+
Description: Kidney from an HIV-infected deceased donor
Study NCT04912297 — intervention group
Intervention type: BIOLOGICAL
Intervention: 10-valent pneumococcal conjugate vaccine, PCV10
Description: 10-valent pneumococcal conjugate vaccine, PCV10
Study NCT02759393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: receiving 8-week PPI
Study NCT00000572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal membrane oxygenation (CO2 removal)
Description: Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
Study NCT04123223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
Study NCT04123223 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Games
Description: Sham placebo treatment
Study NCT01009190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01367338
Description: Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
Study NCT02759393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: receiving 8-week PPI
Study NCT01009190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard doses of intravenous Carboplatin administered every 3 weeks
Study NCT01009190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01367338
Description: RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
Study NCT04149652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Elastosonography
Description: Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
Study NCT03957525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Operative Preparatory Virtual Reality Program
Description: The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
Study NCT03736031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (Promotora)
Description: If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
Study NCT04914169 — intervention group
Intervention type: DEVICE
Intervention: ICRS
Description: The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
Study NCT03100123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin 81 mg po daily in tablet form.
Study NCT03100123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
Study NCT02991573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ceram X
Study NCT01137071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody Hu3S193
Description: 30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation.
Study NCT01443832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fe57 and Fe58-FeSO4 stable isotopes
Description: \[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
Study NCT01808885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olesoxime (TRO19622)
Description: olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit).
Study NCT01808885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule shells with identical appearance as the active compound TRO19622
Study NCT03928626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regulation of craving
Description: Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
Study NCT03928626 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (NO REGULATION)
Description: In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
Study NCT02599623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
Study NCT02599623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
Study NCT01498718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
Study NCT00718341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AF056
Study NCT00718341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo